Multiple Myeloma & MRD
What is Multiple Myeloma?
MM is
a blood cancer
characterized by the clonal expansion of plasma cells in the
bone marrow
. Myeloma is rare, accounting for 1% of all cancers.
MM diagnosis and monitoring
Multiple myeloma diagnosis and monitoring are based on
clinical symptoms
and
a variety of laboratory tests
. M-protein detection and quantification are integral parts of diagnosis and monitoring of MM.
What is MRD ?
MRD stands for
Minimal Residual Disease
. It refers to the
very small number of myeloma cells that are present in the bone marrow after treatment
. These remaining cells often cannot be detected through traditional tests of treatment response. However, they have the
potential to multiply and cause relapse
.
M-inSight®
Resources
About us
Corgenix
CAP/CLIA Clinical Laboratory
: Precision disease monitoring tools powered by advanced proteomics and clinical excellence.
Meet the M-inSight® Team
M-inSight® was developed by a team of myeloma experts and scientific innovators committed to improving how patients are monitored—using advanced technology to deliver clearer, less invasive testing.
Sebia
Center of Excellence for Research and Development
: Our mission is to create advanced tools that translate complex biological signals from the patient’s body into clear, interpretable data.
Contact us
How to order?
Order M-inSight®
Multiple Myeloma & MRD
M-inSight®
Resources
About us
Contact us
How to order?
Order M-inSight®
Back
What is Multiple Myeloma?
MM diagnosis and monitoring
What is MRD ?
Back
Corgenix
Meet the M-inSight® Team
Sebia
Resources
Get helpful information about MRD and M-inSight®
All
Articles
Documentation
Events
Posters
Publications
Documentation
08/28/2025
CAP/CLIA Accreditation for Laboratory Services
ABOUT M-inSight®
Ultra sensitive, Personalized MRD testing in Blood
See what others can't